Monocytes depletion from apheresis products could result in improved outcome of patients with R/R LBCL receiving CD19–directed CAR T cells. ow.ly/HLHO50Rn45A #lymphoidneoplasia #immunobiologyandimmunotherapy

No regimen was associated with statistically superior rwOS. ow.ly/rBgM50RgaJS #lymphoidneoplasia #myeloma

No regimen was associated with statistically superior rwOS. ow.ly/NMNr50R8t2B #lymphoidneoplasia #myeloma #bloodneoplasia

Multiple myeloma–associated DIS3 gene is essential for hematopoiesis, but loss of DIS3 is insufficient for myelomagenesis
ow.ly/W3lL50RgahG #lymphoidneoplasia #myeloma

The signature improves prediction of clinical outcomes compared with other established prognostic indicators regardless of MBL/CLL designation. ow.ly/m9AR50RooWt #lymphoidneoplasia

How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia ow.ly/3Vba50Roppr #HowITreat #lymphoidneoplasia

New signature predicts MBL-to-CLL progression
ow.ly/kcqR50RooSl #lymphoidneoplasia

Ibrutinib in CLL: benefit for all?
ow.ly/QgpW50RjhsO #lymphoidneoplasia

Tisagenlecleucel responses in patients with r/r FL remain highly durable a year after primary analysis; no new safety signals were observed. ow.ly/tbjc50RoplM #clinicaltrialsandobservations #lymphoidneoplasia

Pediatric CD371-positive B-cell precursor acute lymphoblastic leukemia shows transient lineage switch and slow early response to treatment. ow.ly/boEs50Rop6j #lymphoidneoplasia #clinicaltrialsandobservtions #pediatrichematology

Atrial fibrillation and hypertension incidence increase over time with ibrutinib, with an atrial fibrillation rate of 18% at this time. ow.ly/bBAA50RjcQy #lymphoidneoplasia #clinicaltrialsandobservations

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
ow.ly/6WAG50Rjiij #lymphoidneoplasia

Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy
ow.ly/bq3m50RmqWc #immunobiologyandimmunotherapy #lymphoidneoplasia

ABC and GCB subtype sinonasal DLBCL are geno- and phenotypically distinct entities, exhibiting a contrasting disease course and prognosis. ow.ly/lFOO50Rmt9n #lymphoidneoplasia

Real-world applicability of the International Metabolic Prognostic Index in DLBCL: a validation cohort study
ow.ly/E9WX50Rmr2b #lymphoidneoplasia

Peripheral blood regulatory T cells associate with teclistamab failure, whereas CD8+ effector T cells associate with teclistamab response. ow.ly/hogy50RbM1J #lymphoidneoplasia #immunobiologyandimmunotherapy

In publications on BTK and its inhibitors, phosphorylation of tyrosine 223 is often considered necessary for complete catalytic activity. ow.ly/p5nV50Rmttj #immunobiologyandimmunotherapy #lymphoidneoplasia

Low levels of BCR::ABL1 and deletions of B-cell development genes including IKZF1 and PAX5 are associated with tyrosine kinase resistance. ow.ly/Ohv650RmsXx #lymphoidneoplasia #clinicaltrialsandobservations

PI3Kγ/δ and NAMPT inhibitors synergize in blocking AKT activation and induce apoptosis, with potent antitumor activity in RS-PDX models. ow.ly/hKK250Rmt3U #lymphoidneoplasia

Continuous venetoclax monotherapy for untreated or R/R del(17p) CLL led to a median PFS of 28.2 months and median OS of 62.5 months. ow.ly/g39250RmrT8 #clinicaltrialsandobservations #lymphoidneoplasia